Details:
Company has announced the initiation of developing two new biosimilar candidates referencing Keytruda® and Darzalex® respectively. Together with Xdivane™, these new biosimilar candidates form an oncology biosimilar portfolio.
Lead Product(s): Pembrolizumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2021
Details:
The patent application is an outcome of the option agreement that was previously entered into between the two companies regarding Medivir’s preclinical MALT1 project.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Rheos Medicines
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 15, 2021
Details:
Xspray Pharma has received positive preliminary results from a bioavailability study in healthy volunteers with an improved HyNap-Dasa version of the reference drug Sprycel™, demonstrating that absorption of HyNap-Dasa is not dependent on the gastric pH level.
Lead Product(s): Dasatinib
Therapeutic Area: Oncology Product Name: HyNap-Dasa
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 30, 2020
Details:
The two companies will explore the anti-tumor effect of the CD40 antibody mitazalimab (Alligator Bioscience) in combination with SCO-101 (Scandion Oncology) as an add-on to chemotherapy in preclinical tumor models that have been shown to be resistant to chemotherapy.
Lead Product(s): Mitazalimab,SCO-101
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Scandion Oncology
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 04, 2020
Details:
The license agreement includes exclusive rights to an immune-activating antibody directed against a receptor within the TNFR-SF, a collective name for a number of target molecules with similar functions, and applies to the China, Hong Kong, Taiwan and Macau markets.
Lead Product(s): Immune-activating antibody
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Biotheus
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 01, 2020
Details:
The agreement, for an undisclosed amount, includes process development and conjugation of two antibodies in BioInvent's development labs with work expected to start in May 2020.
Lead Product(s): Antibodies
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 30, 2020